MK-2206 2HCl

Catalog No.S1078

MK-2206 2HCl Chemical Structure

Molecular Weight(MW): 480.39

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 570 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 179 Publications

18 Customer Reviews

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

  • The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

    Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

  • VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

    Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

  • Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

    IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

  • Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

    Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

  • A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

    Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

    Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

     

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
Features The first allosteric small molecule inhibitor of Akt to enter clinical development.
Targets
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
In vitro

MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 MY\DfZRwfG:6aXOgRZN{[Xl? NF;CWJM{KM7:TR?= MmLnO|IhcA>? MY\EUXNQ NYHlU|lTUW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36= M3\GfFIxPTdzME[5
A431 NYiyTFRoU2mwYYPlJGF{e2G7 M{GxSlUh|ryP NVHSPYl3PSCq MnnlSG1UVw>? M3nhUnN2eHC{ZYPz[ZMhfGinIIPp[45idGmwZzDv[kBCc3RiYX7kJGVzcw>? MknSNlA2PzFyNkm=
HepG2 MmfYR5l1d3SxeHnjJGF{e2G7 M323VFExKM7:TR?= M4fSdlI1KGh? M37yd2ROW09? MVXT[Y5{cXSrenXzJJJme2m|dHHueEBk\WyuczD0c{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDzc5Ji\mWwaXK= NI[zOZQzOTJyNUmyOS=>
Sk-Hep1 MXzDfZRwfG:6aXOgRZN{[Xl? NVPw[VhLOTBizszN MUiyOEBp M{HRT2ROW09? MoHOV4Vve2m2aYrld{Bz\XOrc4ThcpQh[2WubIOgeI8hfGinIHP5eI91d3irYzDl[oZm[3Rib3[gd49z[W[nbnni MYmyNVIxPTl{NR?=
OCUT1 cells harbored PIK3CA (H1047R+/+) NHzaW3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHGXoRuOyEQvF2= NUTOepIxPSCm M4rodGROW09? MoriTWM2OD1yLkG0JO69VQ>? NWHiTHZUOjF{OEmyOlc>
K1 cells harbored PIK3CA (E542K+/+) M1LJe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVuzJO69VQ>? NIj2fpo2KGR? NWXYfldJTE2VTx?= M3HvN2lEPTB;MD61NkDPxE1? NWLyZYhCOjF{OEmyOlc>
FTC133 cells harbored PTEN (allele deletion and R130+) MlTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[zJO69VQ>? NHT2PYM2KGR? M4jtUGROW09? M4rnOmlEPTB;MD6xPEDPxE1? MVGyNVI5QTJ4Nx?=
C643 cells harbored HRAS (G13R+/−) NV7zdW13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnBNm5nOyEQvF2= MUe1JIQ> NHPwc2NFVVOR NYHofXROUUN3ME2wMlI4KM7:TR?= MXyyNVI5QTJ4Nx?=
Hth7 cells harbored NRAS (Q61R+/−) NWjRN21jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[zJO69VQ>? M{\zOlUh\A>? NE\WSWxFVVOR M3nJTmlEPTB;ND61JO69VQ>? NImz[IIzOTJ6OUK2Oy=>
TPC1 cells harbored RET/PTC1 rearrangement M1X5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVi3TVdyOyEQvF2= MkfMOUBl M{S3PGROW09? NWTJe2c1UUN3ME2wMlU6KM7:TR?= MkjDNlEzQDl{Nke=
Hth74 Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:zJO69VQ>? MXi1JIQ> NXzRVoxCTE2VTx?= NVv0NFNJUUN3ME2yMlE6KM7:TR?= M2Doe|IyOjh7Mk[3
KAT18 M{fu[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\NTpU{KM7:TR?= M1z6c|Uh\A>? M1XyXGROW09? NUCzfpNVUUN3ME20MlYzKM7:TR?= MXOyNVI5QTJ4Nx?=
SW1736 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zrVVExOCEQvF2= Mn7rOUBl MYrEUXNQ MUXJR|UxRTR5LkW2JO69VQ>? NWfVNXc1OjF{OEmyOlc>
WRO M1\HdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHy1UpIyODByIN88US=> NI\te|k2KGR? NIjLbGlFVVOR M4jpfGlEPTB-MUCwNEDPxE1? MV:yNVI5QTJ4Nx?=
TAD2 NXHWfG91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nxTVExODBizszN MkPBOUBl NEPWR|lFVVOR M{LOT2lEPTB-MUCwNEDPxE1? MXmyNVI5QTJ4Nx?=
LN229 NGnscHlCeG:ydH;zbZMhSXO|YYm= Mmn2NE42KM7:TR?= MVi2NEBp MX3EUXNQ NGLRZWlCfWevZX70d{BieG:ydH;n[Y5q[yCnZn\lZ5R{KG:oIHfl[ol1cW6rYh?= M2X1UlIzODV5OUG0
T98G NVj6OZpLSXCxcITvd4l{KEG|c3H5 MnzENE42KM7:TR?= NHHFfFM3OCCq MUjEUXNQ NEjKTJVCfWevZX70d{BieG:ydH;n[Y5q[yCnZn\lZ5R{KG:oIHfl[ol1cW6rYh?= NETDV|YzOjB3N{mxOC=>
HC11 NWexc|dTTnWwY4Tpc44hSXO|YYm= M3;4[FExKM7:TR?= NETpU3ozPCCq NFrBN29FVVOR NUXCSo9mUW6qaXLpeJMh|rJvY3Hz[YlvKGGwZDDBSHJRKHO7boTo[ZNqew>? MlfqNlI1OjZ4MkG=
MOLT-4 M2nUfGN6fG:2b4jpZ{BCe3OjeR?= NXKxZnFtOTBizszN MWG0PEBp NILCRYpFVVOR MVjJR|UxRTFwN,MAje69VQ>? MUKyNlYyPDJ2Mx?=
CEM-R NGrtdGhEgXSxdH;4bYMhSXO|YYm= M2O2blExKM7:TR?= MWq0PEBp MYHEUXNQ NIP2fo1KSzVyPUOuN-KBkc7:TR?= M4PQe|IzPjF2MkSz
CEM-S M1jFWWN6fG:2b4jpZ{BCe3OjeR?= MXSxNEDPxE1? NFHEbGU1QCCq NGjucoxFVVOR MoPNTWM2OD13LkJihKnPxE1? NYjlSnF6OjJ4MUSyOFM>
MOLT-4 M13JS2Z2dmO2aX;uJGF{e2G7 MY[xNEDPxE1? NYn2bpZGOjRiaB?= MU\EUXNQ MWjCcI9kc3NiY3XscJMhcW5idHjlJGcxN0dzIIDoZZNmKG:oIITo[UBk\WyuIHP5Z4xm MWeyNlYyPDJ2Mx?=
MOLT-4 MXjGeY5kfGmxbjDBd5NigQ>? MYG05qCK|ryP M1LJXFQhcA>? NGiwWlJFVVOR NIXMNlhKdmO{ZXHz[ZMhfGinIHHtc5VvfCCxZjDjcIVifmWmIFzDN2EwSixiYTD3[YxtNWW|dHHicIl{cGWmIHH1eI9xcGGpeTDtZZJs\XJ? MVeyNlYyPDJ2Mx?=
CEM-R NHWwWI9HfW6ldHnvckBCe3OjeR?= NIjsd2016oDLzszN M2HNSlQhcA>? NIH5PJlFVVOR MnzvTY5kemWjc3XzJJRp\SCjbX;1cpQhd2ZiY3zlZZZm\CCOQ{TBM2ItKGFid3XscE1me3SjYnzpd4hm\CCjdYTvdIhi\3libXHyb4Vz M1qwelIzPjF2MkSz
CEM-S MnX3SpVv[3Srb36gRZN{[Xl? Mn;COQKBkc7:TR?= NWTPWlVEPCCq MnP1SG1UVw>? M3LNbGlv[3KnYYPld{B1cGViYX3veY51KG:oIHPs[YF3\WRiTFO1RU9DNCCjIIflcIwu\XO2YXLsbZNp\WRiYYX0c5Bp[We7IH3hdotmeg>? MVmyNlYyPDJ2Mx?=
HepG2 cell MX;LbY5ie2ViQYPzZZk> M1PnfFIxKM7:TR?= NXHESVE3OjRiaB?= Mn;ESG1UVw>? NUXnNmRVTG:5boLl[5Vt[XSnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= MV2yN|c6PzNzOR?=
HepG2 cell M33SZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWizNEDPxE1? M1\SfVI1KGh? NWrl[mpXTE2VTx?= NV7UPIRxUW6qaXLpeJMh[2WubDDndo94fGh? Mn;6NlM4QTd|MUm=
HepG2 cell MXTBdI9xfG:|aYOgRZN{[Xl? M1HZc|IxKM7:TR?= NHvncnczPCCq NWfiNVFDTE2VTx?= MYXJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MonUNlM4QTd|MUm=
GEO NVvENFlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFL0[o42ODBibl2= Mle0O|IhcA>? NWnmcXppTE2VTx?= NHHhZYNKdmirYnn0d{Bk\WyuIHfyc5d1cA>? Mne2NlQ2QDF{M{G=
CNE-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\ITZQyOCEQvF2= NFn6fo46PiCq NVvOfm1qTE2VTx?= M2XSNWlEPTB;Mj65OkDPxE1? MVyyOVM{Pjl{NR?=
CNE-2 M32ze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWGxNEDPxE1? NX\nfYg3QTZiaB?= MVPEUXNQ M4nUVWlEPTB;ND61N{DPxE1? NVnSTGdiOjV|M{[5NlU>
HONE-1 Mn3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zs[lExKM7:TR?= MXq5OkBp MnPPSG1UVw>? NIW4V2VKSzVyPUOuN|ch|ryP NIPaOYEzPTN|NkmyOS=>
SUNE-1 MmXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTrNVAh|ryP MnmxPVYhcA>? NWjiXFJITE2VTx?= MWjJR|UxRTBwNUKg{txO MkixNlU{OzZ7MkW=
CNE-2 M4q2WWZ2dmO2aX;uJGF{e2G7 MWqxNEDPxE1? NV33XoN4PDhiaB?= M3K0PWROW09? MUHJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHH0JGcy NXmxS41KOjV|M{[5NlU>
HONE-1 MV3GeY5kfGmxbjDBd5NigQ>? MoPGNVAh|ryP MnzBOFghcA>? MVHEUXNQ M4fyPGlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhTzF? M164cFI2OzN4OUK1
NEC8 MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO3cXE4UUN3ME2wMlA6PjVzIN88US=> NVXsUZd5W0GQR1XS
P12-ICHIKAWA MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwMUG2NkDPxE1? MoHQV2FPT0WU
MDA-MB-175-VII NIPjUWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEi2dHpKSzVyPUCuNVM4OzhizszN MUHTRW5ITVJ?
AsPC-1 NW\QeJpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\ZT2ZsUUN3ME2wMlIzOTJ{IN88US=> NWLQeIx2W0GQR1XS
T47D M1XLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\5TWM2OD1yLkK4NlUh|ryP MUnTRW5ITVJ?
HH NUTHeFlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\HTWM2OD1yLkOwNlg{KM7:TR?= M3T1dHNCVkeHUh?=
MOLT-16 M1PLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEP0b25KSzVyPUCuN|A{OiEQvF2= NGTYRZJUSU6JRWK=
ES5 NWDERmh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfUS3FiUUN3ME2wMlM1PDV3IN88US=> M{nCeHNCVkeHUh?=
RS4-11 M4LVemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3YTWM2OD1yLkO0OlEh|ryP NGjrdVFUSU6JRWK=
KARPAS-45 M{naN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjXbHJLUUN3ME2wMlM4OzJzIN88US=> NWr1U5NrW0GQR1XS
NCI-H720 MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwM{e2O|kh|ryP MX;TRW5ITVJ?
H9 NUf5SGxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33kbGlEPTB;MD6zPFg5OyEQvF2= MUTTRW5ITVJ?
EFM-19 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rXcGlEPTB;MD60OFAyKM7:TR?= NFKxZ41USU6JRWK=
SBC-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2L3e2lEPTB;MD60OFA{PSEQvF2= NVfwRXlxW0GQR1XS
A4-Fuk MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HUUmlEPTB;MD60Olg3QCEQvF2= MWTTRW5ITVJ?
NCI-H1563 MlLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\ne2lEPTB;MD60PFE5QSEQvF2= MlnjV2FPT0WU
HCC1419 MoX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnodopsUUN3ME2wMlQ5QDl{IN88US=> NXOz[pdrW0GQR1XS
H-EMC-SS MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwNEm5N|kh|ryP NEPYcWVUSU6JRWK=
BHT-101 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHzTWM2OD1yLkWyPVYyKM7:TR?= NGHGbmxUSU6JRWK=
IGROV-1 NWLiWpJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoiyTWM2OD1yLkW1NlQ6KM7:TR?= NX;IRWFqW0GQR1XS
HGC-27 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwNU[3PFMh|ryP NVzTbYtoW0GQR1XS
MDA-MB-361 NXHzRmRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnZVJNKSzVyPUCuOVc4PjFizszN M4XESXNCVkeHUh?=
KE-37 NWrmWndDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jLNmlEPTB;MD61PFI3KM7:TR?= NVWzXJcxW0GQR1XS
HCC70 NVzqPGdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1G3dGlEPTB;MD61PVgzPyEQvF2= NYXGXmpjW0GQR1XS
LNCaP-Clone-FGC NFnTNpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfxU|FGUUN3ME2wMlYyODR6IN88US=> MoDnV2FPT0WU
HAL-01 MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPETWM2OD1yLk[yNVMh|ryP NH64W4FUSU6JRWK=
HT MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;XfZR7UUN3ME2wMlY{OjN7IN88US=> NEPKdHhUSU6JRWK=
MDA-MB-415 MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1m5RWlEPTB;MD62N|YzPiEQvF2= MXTTRW5ITVJ?
NOS-1 M4nMS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXKeG5KSzVyPUCuOlM4OjNizszN NGns[4NUSU6JRWK=
DU-145 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TrR2lEPTB;MD62OFc1PSEQvF2= NYG3[oRyW0GQR1XS
OCUB-M NFTu[|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rJdGlEPTB;MD63NFk3PiEQvF2= M1PtRXNCVkeHUh?=
VA-ES-BJ M1[z[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:0XlVGUUN3ME2wMlc{ODJ3IN88US=> NV\CWmJOW0GQR1XS
J-RT3-T3-5 NYW0cINKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofvTWM2OD1yLke0OFA{KM7:TR?= MVrTRW5ITVJ?
MOLT-4 MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwOEC1PFIh|ryP M3eyPHNCVkeHUh?=
NB7 NVfq[HdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoezTWM2OD1yLkiyOFEyKM7:TR?= NYXzZnMyW0GQR1XS
L-363 M1jNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DDUmlEPTB;MD64N|Q1OiEQvF2= NUXoZodlW0GQR1XS
NKM-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;SPIFKSzVyPUCuPFYzPTNizszN MYfTRW5ITVJ?
HOP-92 M1PyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwOEeyNlMh|ryP NWfxNYl5W0GQR1XS
OAW-42 NHPGeY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXK[41KSzVyPUCuPFg4OiEQvF2= NYLVO|NoW0GQR1XS
HuO9 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fFW2lEPTB;MD65Nlc2OSEQvF2= NG\q[mVUSU6JRWK=
MFE-280 NGThW|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3GTnhUUUN3ME2wMlk3PDZ3IN88US=> NVfFeGZmW0GQR1XS
EM-2 M4PZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3aWpFCUUN3ME2wMlk4QTN7IN88US=> Moq5V2FPT0WU
NCI-H520 NWHDVXlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLkNXFrUUN3ME2wMlk5PTl{IN88US=> NX3jTHA6W0GQR1XS
LB2241-RCC NXzXRVMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwOUm3N|Qh|ryP MoTPV2FPT0WU
SK-NEP-1 NUPaOIIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHruUopKSzVyPUGuNVQ1QDVizszN NIK4UJZUSU6JRWK=
LXF-289 NUXkU|Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zwZmlEPTB;MT6xO|E2PiEQvF2= NWj3cmVyW0GQR1XS
EPLC-272H M{fE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYSxdGNKUUN3ME2xMlE4OjV4IN88US=> MVjTRW5ITVJ?
COLO-684 NH7tbG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnGzTWM2OD1zLkKzO|I2KM7:TR?= M1:0[XNCVkeHUh?=
ES1 NEn2T2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvVXFBKSzVyPUGuNlQxPjVizszN M4PLTXNCVkeHUh?=
DOHH-2 MlrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;vTWM2OD1zLkK4NlA{KM7:TR?= NWf6RZQ1W0GQR1XS
CTB-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH1epJKSzVyPUGuNlg6QSEQvF2= MoPTV2FPT0WU
G-401 M{LVXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvTdFBKSzVyPUGuNlk4QTVizszN NH3tW|NUSU6JRWK=
LoVo M12zNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTFwM{K1N|Qh|ryP NIjVV|lUSU6JRWK=
Ramos-2G6-4C10 NUDvRXJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPKc4JKSzVyPUGuN|M4ODFizszN NID4fmlUSU6JRWK=
MFM-223 MkfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXXdIpKSzVyPUGuN|Q1PjFizszN MnP4V2FPT0WU
PA-1 NXHjOXpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7xTWM2OD1zLkO1NlY2KM7:TR?= M{XHWHNCVkeHUh?=
697 Mn;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTFwM{e2NVYh|ryP M2LPVnNCVkeHUh?=
QIMR-WIL NYC4PZNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnroTWM2OD1zLkS5NVE3KM7:TR?= MV3TRW5ITVJ?
HOS MoO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LwSWlEPTB;MT60PVU2QCEQvF2= MkDBV2FPT0WU
DMS-273 M1j0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;6PG9kUUN3ME2xMlUyQTV7IN88US=> M{fjNnNCVkeHUh?=
ME-180 NV3Ue3hJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTFwNU[4PVEh|ryP MVPTRW5ITVJ?
HCC2218 M2rFbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTFwNkiyNlUh|ryP NXGyOGRTW0GQR1XS
CAL-54 MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULGPYVIUUN3ME2xMlcyOjR{IN88US=> NHvUW4pUSU6JRWK=
OMC-1 NIG3Tm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTFwN{S2O|ch|ryP MnS0V2FPT0WU
COR-L105 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTFwN{m3N|ch|ryP NX\BOHBMW0GQR1XS
BV-173 M4nw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7WNVZ[UUN3ME2xMlgyODd2IN88US=> NH\hNW5USU6JRWK=
RKO MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTjTWM2OD1zLki3NVAyKM7:TR?= MU\TRW5ITVJ?
SNU-387 MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\5RmlEPTB;MT64PFQxPiEQvF2= MX\TRW5ITVJ?
SW1088 MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvqcnNrUUN3ME2xMlk1PjB4IN88US=> NFrVcVlUSU6JRWK=
Hs-578-T NVHEd2ZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;iTWM2OD1{LkGxOFM{KM7:TR?= M3GzVXNCVkeHUh?=
OC-314 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDEUYJKSzVyPUKuNVUxQDZizszN M{\wRnNCVkeHUh?=
RMG-I M2OyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLYTWM2OD1{LkG2N|k5KM7:TR?= MUjTRW5ITVJ?
NCI-H1395 M1PmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTJfmNqUUN3ME2yMlE5ODlzIN88US=> MV3TRW5ITVJ?
GAMG NXfyZZRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\heHN2UUN3ME2yMlI{QDR3IN88US=> MYDTRW5ITVJ?
LB1047-RCC M1S3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLOTWM2OD1{LkK0N|E4KM7:TR?= M4XTWHNCVkeHUh?=
MN-60 NVvxVIk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJwMkm5NlMh|ryP NF\RV|JUSU6JRWK=
OAW-28 NXzDOmtrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ju[2lEPTB;Mj6yPVk2OSEQvF2= NHzzc3BUSU6JRWK=
NCI-H2228 NVTJbmFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnuO4p6UUN3ME2yMlMyPTV{IN88US=> NGDMTlNUSU6JRWK=
ABC-1 M2rKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXyTWM2OD1{LkOzNlU{KM7:TR?= Mlr3V2FPT0WU
LS-513 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGn1R5hKSzVyPUKuN|M1QDRizszN NH;EXWlUSU6JRWK=
KS-1 MnXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf0TYNKSzVyPUKuN|gyQTFizszN M2q2RnNCVkeHUh?=
NB69 NXSyPXZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXLVotKSzVyPUKuN|g6QDNizszN NX3h[Io1W0GQR1XS
VM-CUB-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLiTWM2OD1{LkO5NFg{KM7:TR?= NHGxcItUSU6JRWK=
D-423MG MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJwNEGwOFQh|ryP MWrTRW5ITVJ?
EW-18 NEf3d2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTJwNEG5N|kh|ryP MlfHV2FPT0WU
YH-13 NIX1dm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonOTWM2OD1{LkS2NVU{KM7:TR?= NHS5XHVUSU6JRWK=
T-24 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJwNEe4PFEh|ryP NVHrdlZzW0GQR1XS
ES8 NF[3U25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzrPGNoUUN3ME2yMlQ6Ojh5IN88US=> MoTvV2FPT0WU
ES3 NX7seoV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\4TWM2OD1{LkS5O|U6KM7:TR?= MWjTRW5ITVJ?
RXF393 NHX4To5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJwNkC0PFch|ryP NYTKWJp2W0GQR1XS
RPMI-8226 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHOem5UUUN3ME2yMlYzQTV|IN88US=> MlXCV2FPT0WU
AGS NHXzOWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M175WGlEPTB;Mj63NlE{PyEQvF2= NHfpfFlUSU6JRWK=
HCC1395 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTnRXlkUUN3ME2yMlc2OTh5IN88US=> M{C1T3NCVkeHUh?=
MV-4-11 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF6yemNKSzVyPUKuO|UzPjZizszN M3rSOnNCVkeHUh?=
A204 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTJwOEO4O|Ih|ryP NFTm[pdUSU6JRWK=
MCF7 M2PlPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLsNZdKSzVyPUKuPFYyOTdizszN MlfMV2FPT0WU
SNU-423 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\RTWM2OD1{Lki5NlQzKM7:TR?= MUnTRW5ITVJ?
NCI-H1048 MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXVVY8xUUN3ME2yMlk3QDZ3IN88US=> M{LDVXNCVkeHUh?=
GR-ST NITQdmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTNwMES2NVEh|ryP MYDTRW5ITVJ?
EoL-1- M{flUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjxe|dKSzVyPUOuNFcxPThizszN MkfMV2FPT0WU
HuH-7 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TPVWlEPTB;Mz6wPVQ3PCEQvF2= MXTTRW5ITVJ?
OS-RC-2 NXOzTHpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\rOGxiUUN3ME2zMlEyOTlizszN Mn65V2FPT0WU
EW-3 NGnkcY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7k[Vc5UUN3ME2zMlE6PTJ7IN88US=> NVnNc5FpW0GQR1XS
NCI-H747 M1;kSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTNwMkC2PVQh|ryP MmfLV2FPT0WU
EW-16 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXj5ZldlUUN3ME2zMlIyQDd7IN88US=> MlS0V2FPT0WU
DOK MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUi1UIs4UUN3ME2zMlIzQDV7IN88US=> MUXTRW5ITVJ?
HCC2157 MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorDTWM2OD1|LkO4NVc6KM7:TR?= MU\TRW5ITVJ?
OVCAR-3 MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLyXXVtUUN3ME2zMlQxPzh4IN88US=> MoH2V2FPT0WU
NCI-H1623 MoSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XZZ2lEPTB;Mz60NVIzPCEQvF2= MoXZV2FPT0WU
H4 NUf4VpFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\JTWM2OD1|LkS1OlI3KM7:TR?= M3W5V3NCVkeHUh?=
SW1710 NGO2S2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLCdXVuUUN3ME2zMlQ3Pjd6IN88US=> NF;nc|VUSU6JRWK=
RT-112 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTNwNUKzPFgh|ryP Mn3oV2FPT0WU
DMS-114 NGS0O4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rSNWlEPTB;Mz62NlI4QCEQvF2= MnvOV2FPT0WU
AN3-CA NV\ac2NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLyTWM2OD1|Lk[yOFU3KM7:TR?= NUX1TZNDW0GQR1XS
KNS-62 M3XGNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETxdJNKSzVyPUOuOlM{OzhizszN M324U3NCVkeHUh?=
SJRH30 MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXnTWM2OD1|Lk[5NVIzKM7:TR?= MVXTRW5ITVJ?
G-402 NGX0XItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{f3V2lEPTB;Mz63NFcyOSEQvF2= NHr3cItUSU6JRWK=
MHH-PREB-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTNwN{KwN|gh|ryP M1LXT3NCVkeHUh?=
P30-OHK MnvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7KNFkyUUN3ME2zMlgxQTd4IN88US=> MUfTRW5ITVJ?
RVH-421 NGL1RVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvudGZKSzVyPUOuPFE4QDhizszN MlPGV2FPT0WU
LU-134-A NHXjWWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHqzRWtKSzVyPUOuPFg1OjhizszN M3XCZXNCVkeHUh?=
ECC10 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoToTWM2OD1|LkmzOlIzKM7:TR?= M4TxT3NCVkeHUh?=
TGW NEn0V5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L0cWlEPTB;ND6wNlMxPSEQvF2= M1L5U3NCVkeHUh?=
MLMA MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjCeoJJUUN3ME20MlAzQTZ4IN88US=> M1nKdHNCVkeHUh?=
SCC-25 NG\lcYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVn1WFBoUUN3ME20MlA3PTZ4IN88US=> MWXTRW5ITVJ?
TYK-nu MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTtdYdKSzVyPUSuNFk2OzRizszN Mlu0V2FPT0WU
LAMA-84 NYn4NFJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDLTWM2OD12LkG0NVkyKM7:TR?= M1;iO3NCVkeHUh?=
Calu-3 NVrm[odGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml76TWM2OD12LkK0OFE3KM7:TR?= MUXTRW5ITVJ?
NCI-H460 Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzyTWM2OD12LkK2OFQ{KM7:TR?= M2LPPHNCVkeHUh?=
EGI-1 NHjHVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnKxTWM2OD12LkO3O|c5KM7:TR?= NIrKRnlUSU6JRWK=
NCI-H292 MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIL5XmRKSzVyPUSuN|gyPDZizszN MmLHV2FPT0WU
HCE-T M2PBemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXJTINKSzVyPUSuOFE2PzlizszN MWTTRW5ITVJ?
EW-11 NIrUbplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH4V3I5UUN3ME20MlQyQDN6IN88US=> NUT3bIxuW0GQR1XS
ATN-1 NInhNINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTRwNESzNFQh|ryP NVfoZZBvW0GQR1XS
NB5 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M16zZWlEPTB;ND61N|Y6PyEQvF2= M{\LbnNCVkeHUh?=
KLE NGHlSY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XaSWlEPTB;ND63NFE6QCEQvF2= MXXTRW5ITVJ?
CAL-39 NV:wWIY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTlW2NKSzVyPUSuO|IyPDZizszN M1nFSnNCVkeHUh?=
TI-73 NG\lXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\kXmlEPTB;ND64NFYxQSEQvF2= M{LNenNCVkeHUh?=
HO-1-N-1 M1XsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIH5c21KSzVyPUSuPVQzKM7:TR?= M1fUdHNCVkeHUh?=
786-0 MnPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTRwOUS2O|Mh|ryP NVvRW49JW0GQR1XS
SK-N-DZ M4P3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTRwOU[xOFIh|ryP MkfYV2FPT0WU
NCI-H446 NFLqUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETKVpBKSzVyPUWuNlAxODlizszN NXTRbmlGW0GQR1XS
ETK-1 MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTVwMkGxOlUh|ryP MUXTRW5ITVJ?
BT-20 NF7DOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTVwMkGzOVMh|ryP NFnPOplUSU6JRWK=
MEL-HO NEHOc2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PVfWlEPTB;NT6zO|M{PiEQvF2= M{HUWHNCVkeHUh?=
CAL-27 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTVwNE[zN|kh|ryP MlfpV2FPT0WU
SW872 NV3kRYpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnuTWM2OD13LkW5OFI5KM7:TR?= M3nOZXNCVkeHUh?=
RPMI-2650 Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTVwNk[xPVkh|ryP MYLTRW5ITVJ?
PFSK-1 NIniUmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\mPZdiUUN3ME21MlczPzN{IN88US=> M{niXnNCVkeHUh?=
SF295 M1PmbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUC1eItVUUN3ME21MlgxPjN|IN88US=> NX3MPW9VW0GQR1XS
Becker MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3KSpE3UUN3ME21Mlg3PDd{IN88US=> M2T5NXNCVkeHUh?=
Saos-2 NFHPNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELYPGlKSzVyPUWuPFY2OyEQvF2= NF6ySohUSU6JRWK=
SK-OV-3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rIPGlEPTB;NT65PVgyPiEQvF2= NXfrN21tW0GQR1XS
VMRC-RCZ M4TwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjOSWdKSzVyPU[uNFg4PzNizszN M2fSenNCVkeHUh?=
EW-22 NVm3bGw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zDV2lEPTB;Nj6xPVY1QSEQvF2= Ml\6V2FPT0WU
BT-474 M{X0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\Mc2lEPTB;Nj6yN|Mh|ryP MYDTRW5ITVJ?
BFTC-909 M2TmR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGO4W|RKSzVyPU[uN|A{PDVizszN M2nCPXNCVkeHUh?=
NB12 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTZwM{mwO|Eh|ryP MmHaV2FPT0WU
D-263MG M2TIcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TB[GlEPTB;Nj60OVE3QSEQvF2= NHz0NWZUSU6JRWK=
SNB75 MoTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvTUZZ2UUN3ME22MlYxOTR|IN88US=> MkGyV2FPT0WU
A704 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrGTWM2OD14Lk[zNFYh|ryP NF[5V2RUSU6JRWK=
NCI-H1693 M1jy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH0d49ZUUN3ME22MlY{PjB2IN88US=> NWS3WFA6W0GQR1XS
LN-405 NF3oOJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\LPWlEPTB;Nj63PVY4OiEQvF2= NX21NYVLW0GQR1XS
CHL-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfITWM2OD14LkiwNFc6KM7:TR?= NH;YfHNUSU6JRWK=
A498 NH7TRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGP2[XpKSzVyPU[uPFE6PjFizszN NU\VfmlQW0GQR1XS
TE-12 MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXoTWM2OD14LkizPFE4KM7:TR?= NEHRe|FUSU6JRWK=
TE-6 NIrQXY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDDTWM2OD14LkmzNFM5KM7:TR?= MXnTRW5ITVJ?
AU565 NHXWPYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\Se41KSzVyPU[uPVY6PTdizszN NF7JV|BUSU6JRWK=
RD NVe0TpVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTZwOUiyPFQh|ryP NXvqRplvW0GQR1XS
SW1463 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrSXYZyUUN3ME23MlEyOTZ6IN88US=> NGq2c5RUSU6JRWK=
LU-99A NX\4UlRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTqTWM2OD15LkG0N|IzKM7:TR?= MXHTRW5ITVJ?
NCI-H28 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGWwXnRKSzVyPUeuNlkzPCEQvF2= M1;5enNCVkeHUh?=
MC-IXC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfROXZKSzVyPUeuOFg2PzZizszN MVTTRW5ITVJ?
GP5d MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorLTWM2OD15LkS4O|Y1KM7:TR?= MnH4V2FPT0WU
GB-1 NXnnTGg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXQR|EzUUN3ME23MlU1QDB2IN88US=> NHTNNYpUSU6JRWK=
CAL-33 NGXXcJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\1WVBKSzVyPUeuOlYzOzNizszN MY\TRW5ITVJ?
MSTO-211H NHrwNG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnaTWM2OD15Lk[3N|M3KM7:TR?= NHvHVGdUSU6JRWK=
TE-5 MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jaXmlEPTB;Nz63PVM{PCEQvF2= MWjTRW5ITVJ?
D-566MG M{\kbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;E[|JwUUN3ME24MlA1PDJ7IN88US=> Mn:5V2FPT0WU
JVM-3 MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRThwMUWyOlgh|ryP MYTTRW5ITVJ?
T98G MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRThwMUiwOlch|ryP MUjTRW5ITVJ?
HCC1954 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoSwTWM2OD16LkS1NVA1KM7:TR?= NXHVNYh4W0GQR1XS
SF126 NYTJXXVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnZTWM2OD16LkS1PVM3KM7:TR?= MXLTRW5ITVJ?
LB996-RCC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRThwNUOyOVch|ryP NFS3OVJUSU6JRWK=
SKG-IIIa MlLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvUZWpzUUN3ME24MlY{ODZ7IN88US=> MXLTRW5ITVJ?
NCI-SNU-1 MmDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRThwNkS2OFMh|ryP Mo\RV2FPT0WU
LB771-HNC MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXj[XVKSzVyPUiuOlQ3QTZizszN NHPibGlUSU6JRWK=
SCC-4 M4jnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRThwNkiyNVkh|ryP NH31e3JUSU6JRWK=
CAMA-1 NV\BVFJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fiZ2lEPTB;OD63O|E1PiEQvF2= MkDPV2FPT0WU
D-502MG NXO1SVlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLUTWM2OD16Lke4OlI6KM7:TR?= MUfTRW5ITVJ?
ESS-1 NV;FVG5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nKS2lEPTB;OD64PFcxPCEQvF2= M1jlfXNCVkeHUh?=
HEC-1 M{HZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRThwOEm4OlYh|ryP NFjEUoZUSU6JRWK=
NB10 M1Xabmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;N[GlEPTB;OT6wNlIzPCEQvF2= NWXQWldEW0GQR1XS
8505C NH;SO4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M362fGlEPTB;OT6wOFI{OiEQvF2= NXvMN2NuW0GQR1XS
EFO-27 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoWyTWM2OD17LkG2OFEzKM7:TR?= MV3TRW5ITVJ?
HN MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7xempUUUN3ME25MlE3PjJ6IN88US=> NFjkNJZUSU6JRWK=
DSH1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfVUXV7UUN3ME25MlIxQDdizszN M1nFNXNCVkeHUh?=
NBsusSR NF;2foRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4OwOGlEPTB;OT6yO|QxOiEQvF2= NUjjUmJQW0GQR1XS
LS-123 NHXVcZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInkUm1KSzVyPUmuN|E4PjFizszN M1HsO3NCVkeHUh?=
SHP-77 NVTYVYpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTlwM{m5N|Uh|ryP NHfMbVdUSU6JRWK=
ACN MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTlwNUOyO|ch|ryP MmrCV2FPT0WU
U251 NEKzdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrLUoFKSzVyPUmuOlU2PDRizszN NGrMNJRUSU6JRWK=
A431 M{O2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37MbGlEPTB;OT64NFI{QCEQvF2= MkDTV2FPT0WU
5637 NFLaOopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnCe4JKSzVyPUmuPFQ6QDRizszN NH6wV4VUSU6JRWK=
MDA-MB-157 M1rZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrYUpJKSzVyPUmuPVI5PzhizszN MVHTRW5ITVJ?
A101D M1HiU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3u2fGlEPTB;OT65PVk4PCEQvF2= MWHTRW5ITVJ?
YKG-1 NWfj[ppYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLvTWM2OD1zMD6yNFA3KM7:TR?= NH3VTYdUSU6JRWK=
LAN-6 Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fkO2lEPTB;MUCuNlE3PCEQvF2= NXLWVGtwW0GQR1XS
OVCAR-5 NHXDZohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTFyLkK0N|Mh|ryP NHq5e5RUSU6JRWK=
A549 MlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfVTWM2OD1zMD6zPVc{KM7:TR?= M3[2dHNCVkeHUh?=
no-11 MkX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDZN216UUN3ME2xNE41OzV|IN88US=> MV3TRW5ITVJ?
SF539 NXL0U2dmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTFyLkmwOFEh|ryP NYLUZ|BxW0GQR1XS
A388 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPyZ2JmUUN3ME2xNU4{QDl5IN88US=> NFL4S4FUSU6JRWK=
DEL NFXwVXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fJSGlEPTB;MUGuOFI1KM7:TR?= NX[1Z3B3W0GQR1XS
SW954 MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTFzLkS2Olgh|ryP NVjoe|gxW0GQR1XS
TK10 NFWxZZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrmZnBKSzVyPUGxMlUzPzFizszN MWLTRW5ITVJ?
SW756 M2nzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTFzLkWyPVQh|ryP NH3ZU3hUSU6JRWK=
PC-3 NVXVdGs5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnqXHRTUUN3ME2xNU42PzZ2IN88US=> M4K1N3NCVkeHUh?=
ONS-76 NHLWZ5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTFzLk[zOkDPxE1? M3[1RnNCVkeHUh?=
A427 M3PnNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjHVFNKSzVyPUGxMlcxQTNizszN M4rNUXNCVkeHUh?=
MEG-01 M3PwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvwTWM2OD1zMT63OVA6KM7:TR?= NFTx[XRUSU6JRWK=
BB30-HNC MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfMT|RKSzVyPUGxMlc6QDJizszN NInOe4tUSU6JRWK=
NCI-H1299 NFXsfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Lz[mlEPTB;MUGuPFA6OyEQvF2= MmH3V2FPT0WU
GCT M3TpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M122SmlEPTB;MUGuPFIzQCEQvF2= M1LTXnNCVkeHUh?=
D-247MG M13yeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TFWWlEPTB;MUGuPVY3OyEQvF2= NEfHUWZUSU6JRWK=
CFPAC-1 MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3yyOmlEPTB;MUGuPVc5OiEQvF2= M{DLW3NCVkeHUh?=
EKVX MnfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF{LkCzNVMh|ryP NUjSNIV[W0GQR1XS
CAL-51 NGLWXplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXpfmtKSzVyPUGyMlA4OTZizszN MWPTRW5ITVJ?
BB49-HNC M1\MPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljXTWM2OD1zMj6xNVc4KM7:TR?= MWLTRW5ITVJ?
RPMI-7951 NWniWGNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvLeYRKSzVyPUGyMlE5PTRizszN MWjTRW5ITVJ?
RH-1 M4G5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TU[2lEPTB;MUKuNlE5PCEQvF2= MYnTRW5ITVJ?
BCPAP NVXzOFl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV30ZpEzUUN3ME2xNk41PzR7IN88US=> NFvzd4tUSU6JRWK=
GCIY MlrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DBSGlEPTB;MUKuOVIxQSEQvF2= NHXEVHVUSU6JRWK=
KNS-81-FD MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF{LkW4Olkh|ryP NWXydZM1W0GQR1XS
KYSE-140 NYO4S|NZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFz3NJBKSzVyPUGyMlg2QTVizszN NF:5Xo1USU6JRWK=
Ca-Ski NFLGbGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoraTWM2OD1zMj65NFQyKM7:TR?= NVfXNGdsW0GQR1XS
TGBC1TKB M1zXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\1b2lEPTB;MUKuPVEyPSEQvF2= NXjBSW1JW0GQR1XS
HCC1187 NFX4OHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF|LkG5NVIh|ryP MWnTRW5ITVJ?
SJSA-1 MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF|LkKzNlch|ryP M3HIcXNCVkeHUh?=
CTV-1 M3vWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{W3WmlEPTB;MUOuN|Q2KM7:TR?= NUDwc3BQW0GQR1XS
WM-115 NF6xT|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV36WIsxUUN3ME2xN{43PDh|IN88US=> M2Gwb3NCVkeHUh?=
CHP-212 NGnSNYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkG3TWM2OD1zMz65O|M6KM7:TR?= Ml\nV2FPT0WU
SCC-15 NF;KU3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTF|Lkm3O|Uh|ryP MYTTRW5ITVJ?
BPH-1 M4C0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTF2LkG2OlQh|ryP NFjL[3hUSU6JRWK=
SW780 NWjzVnRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFO3fGJKSzVyPUG0MlUxOjVizszN Mn3UV2FPT0WU
NCI-H2291 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojkTWM2OD1zND61PFc5KM7:TR?= M3fuOXNCVkeHUh?=
JEG-3 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfMTWM2OD1zND62N|I3KM7:TR?= M4PVXHNCVkeHUh?=
CAL-120 NEPwb2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTF2LkewNlch|ryP NYnlXFVYW0GQR1XS
NCI-H23 NXLoNnpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTF2Lke5PVch|ryP MXHTRW5ITVJ?
MS-1 NVnPeGVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4D1O2lEPTB;MUSuPVYyOSEQvF2= MVPTRW5ITVJ?
PC-14 NVXzRmx{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTF2Lkm2OVQh|ryP Mn7lV2FPT0WU
D-283MED M1fGWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTF3LkCxNVEh|ryP MX\TRW5ITVJ?
OE19 M{j2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTF3LkG1OFEh|ryP NX;Ob5d3W0GQR1XS
CAS-1 NYXNfJpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{CzUWlEPTB;MUWuOFE5PCEQvF2= MWPTRW5ITVJ?
NCI-H727 MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3KXml7UUN3ME2xOU41OjJzIN88US=> NX;Yeno{W0GQR1XS
SiHa NWnFU2ZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4O0emlEPTB;MUWuO|U6PCEQvF2= MXXTRW5ITVJ?
BFTC-905 NGXHXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPyTWM2OD1zNT63Olk1KM7:TR?= NXvFNZZDW0GQR1XS
MDA-MB-453 M1HnSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4T5cmlEPTB;MU[uNVY1OiEQvF2= NX3DRVJiW0GQR1XS
HuP-T3 NUDVPFU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLJTWM2OD1zNj62N|c{KM7:TR?= NWq5SYRIW0GQR1XS
SK-LU-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknQTWM2OD1zNj62PVU3KM7:TR?= NYrlV|lSW0GQR1XS
Detroit562 NEPJTYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jkR2lEPTB;MU[uO|MyQCEQvF2= NXT2VWJqW0GQR1XS
HCC1569 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIS1TFZKSzVyPUG2Mlg{OzdizszN M{S4S3NCVkeHUh?=
SK-MES-1 MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHruWYVKSzVyPUG2Mlg1OTlizszN NXfu[JdqW0GQR1XS
BB65-RCC NUXZbVdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnkTWM2OD1zNz6wOFc6KM7:TR?= NXf2dVFpW0GQR1XS
LOXIMVI M1fHXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTF5LkC3NFch|ryP NYC3fVVqW0GQR1XS
SW1783 NFzWeHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHw[FZzUUN3ME2xO{4yOjhizszN MlroV2FPT0WU
NH-12 M4S0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTnTWdlUUN3ME2xO{4{OzB|IN88US=> M4\ZVHNCVkeHUh?=
UACC-257 NGq2XZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF5LkW1NVIh|ryP M1LMRXNCVkeHUh?=
KOSC-2 MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTF5Lk[3OVch|ryP M4HLSXNCVkeHUh?=
KG-1 M1L5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjCSpJKSzVyPUG3MlY6OzdizszN MkPFV2FPT0WU
M059J NXjx[nRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHZTWM2OD1zNz63NFMh|ryP M4\VfnNCVkeHUh?=
MHH-NB-11 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLaTWM2OD1zNz65Olc{KM7:TR?= MofiV2FPT0WU
EW-1 NFLGRmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTF6LkGzPFIh|ryP NHvvRYlUSU6JRWK=
CAL-85-1 NGLoOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTF6LkKzOVch|ryP NIqzeIRUSU6JRWK=
639-V NHHR[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWiyOVZwUUN3ME2xPE4{OzV2IN88US=> M1nhOnNCVkeHUh?=
C32 MmLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTF6LkS3Nlch|ryP M1G2ZXNCVkeHUh?=
KM-H2 NX\ufnlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXSzdHY4UUN3ME2xPE42OjN{IN88US=> MWPTRW5ITVJ?
A253 MoXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXK2R4hGUUN3ME2xPE44Ojh4IN88US=> NEHZbmxUSU6JRWK=
NCI-N87 NV7RPGFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTF6LkmwNFgh|ryP NVjPPWttW0GQR1XS
8-MG-BA NVizNmJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLWPGgxUUN3ME2xPU4xPjR4IN88US=> MXTTRW5ITVJ?
GI-ME-N Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfBTlMzUUN3ME2xPU4yPTR4IN88US=> NIDmXXhUSU6JRWK=
8305C MnfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPjTW1KSzVyPUG5MlIzQDZizszN NUWzN5N7W0GQR1XS
TE-8 NEjGSGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHCd4xKSzVyPUG5MlMxOjRizszN NGf3b4VUSU6JRWK=
KYSE-270 M371Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fGdWlEPTB;MkCuNFIyPyEQvF2= NUe2UGtjW0GQR1XS
HL-60 MoG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HrWGlEPTB;MkCuNFk1OSEQvF2= NGP3R|VUSU6JRWK=
Mo-T NWe1elU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWf1eHc1UUN3ME2yNE4yPjZ3IN88US=> NWLuWpI{W0GQR1XS
NCI-H1355 MnuwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJyLkOzO|Qh|ryP M1jDXXNCVkeHUh?=
HT-1080 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnT1TWM2OD1{MD61OFk4KM7:TR?= NGfMOo9USU6JRWK=
MIA-PaCa-2 NH[4OJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHG4[YRKSzVyPUKwMlY5QDNizszN NYjYbmpbW0GQR1XS
NCI-H441 NFnYXo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTJyLkezO|kh|ryP MXzTRW5ITVJ?
LCLC-97TM1 Mm\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJyLkixN|Qh|ryP NULMN4xwW0GQR1XS
HT-3 M3TJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2f4WmlEPTB;MkGuOVY{OSEQvF2= NFryW|NUSU6JRWK=
22RV1 MmfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojGTWM2OD1{MT61Olg2KM7:TR?= MlTLV2FPT0WU
LK-2 M3TDdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTJzLkW5OVMh|ryP NVHodYNEW0GQR1XS
CW-2 NEnvbZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XaS2lEPTB;MkGuOlA3QSEQvF2= M{f4RnNCVkeHUh?=
KYSE-510 M{nOUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTJzLk[wPVUh|ryP NFXVOlBUSU6JRWK=
CGTH-W-1 MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\jeGc3UUN3ME2yNU44OTZ4IN88US=> Mle4V2FPT0WU
NCI-H661 MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1e1UGlEPTB;MkKuNFM1KM7:TR?= NUPvcpFTW0GQR1XS
KU-19-19 NGixbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DBWWlEPTB;MkKuNVY6PyEQvF2= M4PxO3NCVkeHUh?=
NCI-H2122 M{LjdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJ{LkK0N|Ih|ryP NGq3dHJUSU6JRWK=
NCI-H526 NHvQfYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLDTWM2OD1{Mj6zPFk2KM7:TR?= MX;TRW5ITVJ?
NCI-H1650 NF3VOHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTJ{Lke2OEDPxE1? MnrUV2FPT0WU
AM-38 NXP6UGtiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlT0TWM2OD1{Mj64Olg6KM7:TR?= MYHTRW5ITVJ?
NCI-H2405 NF3tZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTJ|LkK1N|Mh|ryP NITuOIJUSU6JRWK=
M14 M2PWTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHJ[WtGUUN3ME2yN{41ODh6IN88US=> MoHtV2FPT0WU
ES4 M1jCXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTJ|LkSyN|Ih|ryP M3T5fnNCVkeHUh?=
DJM-1 M2H3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmWwTWM2OD1{Mz61NlM1KM7:TR?= MUDTRW5ITVJ?
S-117 MoO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrnTWM2OD1{Mz63OlUyKM7:TR?= NWP1SVdTW0GQR1XS
MZ2-MEL Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfXOXdnUUN3ME2yN{44PzV7IN88US=> M4fteHNCVkeHUh?=
SK-MEL-2 M2DzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfNTWM2OD1{Mz64NVM{KM7:TR?= NHSzRXVUSU6JRWK=
HCC1806 NUKyVHc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPWfY1kUUN3ME2yN{45PzB7IN88US=> MUjTRW5ITVJ?
NMC-G1 M2rMVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTJ2LkKyNlYh|ryP M2n5enNCVkeHUh?=
DK-MG NVPWNmV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HkVGlEPTB;MkSuNlk1KM7:TR?= M1nhW3NCVkeHUh?=
SK-N-FI MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTJ2LkOzNFIh|ryP NUjVRYlRW0GQR1XS
KINGS-1 Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJ2LkS4O|Qh|ryP NVr6WZFTW0GQR1XS
HCC2998 MonRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Tnb2lEPTB;MkSuOFg5PSEQvF2= MkKyV2FPT0WU
ALL-PO MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{f5NGlEPTB;MkSuOlE6KM7:TR?= M3z4dXNCVkeHUh?=
MPP-89 M1jRW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkD3TWM2OD1{NT6wOFU5KM7:TR?= MlKwV2FPT0WU
NCI-H2342 MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTJ3LkG5OVMh|ryP Mn\ZV2FPT0WU
TE-1 Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7jco9KSzVyPUK1MlM2PjNizszN MnXkV2FPT0WU
RH-18 MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfYTWM2OD1{NT61PVE5KM7:TR?= NYSyVpRsW0GQR1XS
HT-1376 MlnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvmTpFKSzVyPUK1MlY1PjVizszN MljtV2FPT0WU
U-2-OS M1:zSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTlTWM2OD1{NT62PFg5KM7:TR?= M2r3cnNCVkeHUh?=
BT-549 NVXZc|VpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7tNm9ZUUN3ME2yOU46ODFzIN88US=> NWrESpV2W0GQR1XS
NCI-H1755 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFn4emhKSzVyPUK1Mlk6PDVizszN M3T6N3NCVkeHUh?=
EW-13 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlT6TWM2OD1{Nj6wNlc1KM7:TR?= MWDTRW5ITVJ?
NB13 NIr1cGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\pbGlEPTB;Mk[uNFk1QSEQvF2= NY[4U5BNW0GQR1XS
NUGC-3 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTJ4LkKxNFMh|ryP NV2yUINSW0GQR1XS
GMS-10 NGLaZ|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\LTWM2OD1{Nj6yN|U{KM7:TR?= NHHkV4NUSU6JRWK=
CHP-134 MnPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDxTWM2OD1{Nj6zPFY4KM7:TR?= MVvTRW5ITVJ?
SW962 M4DESGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDQV2J[UUN3ME2yOk42ODJzIN88US=> NELYSWpUSU6JRWK=
SNU-449 MkLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3vTWM2OD1{Nz6wPFA{KM7:TR?= MWHTRW5ITVJ?
HuP-T4 NVjmS5AyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\4XIZNUUN3ME2yO{4xQDd7IN88US=> NUe5VZNCW0GQR1XS
SW948 NW[2N4pXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TjdmlEPTB;MkeuNVM1PCEQvF2= NVzNUXNnW0GQR1XS
NCI-H226 MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrt[FNKSzVyPUK3MlQ2PzhizszN NG\KS2dUSU6JRWK=
SK-PN-DW Mn3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rlbWlEPTB;MkeuOlAyOiEQvF2= MULTRW5ITVJ?
GI-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTJ5LkeyNUDPxE1? MXvTRW5ITVJ?
CAL-12T NVvtRnRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnn5TWM2OD1{OD6xNVEzKM7:TR?= M2noUXNCVkeHUh?=
YAPC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP4S4RKSzVyPUK4MlI2PjRizszN MVjTRW5ITVJ?
SNU-C2B MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGft[IRKSzVyPUK4MlI6PjRizszN M12wd3NCVkeHUh?=
RCC10RGB MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPzTWM2OD1{OD61OFE4KM7:TR?= Ml[wV2FPT0WU
ES7 NWLpOJdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fZNmlEPTB;MkmuNVQ3PSEQvF2= MX\TRW5ITVJ?
PANC-03-27 NIPFRoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[1dVZXUUN3ME2yPU41PDRizszN M3PnSXNCVkeHUh?=
ES6 NH7DSJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjienVKSzVyPUK5MlgyPTdizszN NGD6U3NUSU6JRWK=
HT-1197 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYH5OFN4UUN3ME2zNE4xPTl6IN88US=> MVPTRW5ITVJ?
ZR-75-30 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTNyLkKzPFMh|ryP NEjV[3hUSU6JRWK=
DB MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLBTWM2OD1|MD60PVQzKM7:TR?= NFqxeG5USU6JRWK=
OCI-AML2 Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPUVoU5UUN3ME2zNU4xPjlizszN NH\SSY9USU6JRWK=
NCI-H2170 M3i3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\XfGhEUUN3ME2zNU45PTF4IN88US=> M2[4XnNCVkeHUh?=
IST-MES1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1P3SGlEPTB;M{KuNlg6PyEQvF2= NUHPN3ozW0GQR1XS
769-P NF7oUY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPnTWM2OD1|Mj6zOlQyKM7:TR?= MWTTRW5ITVJ?
COR-L23 NYS2N2FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7BdmVKSzVyPUOyMlkxPzNizszN NGfvU41USU6JRWK=
SW626 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPCTWM2OD1|Mz6xO|c3KM7:TR?= NUDqfGw3W0GQR1XS
LU-139 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4C0VWlEPTB;M{OuOlYxPSEQvF2= NITpW5lUSU6JRWK=
HT-144 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljoTWM2OD1|Mz64OlMh|ryP MoXRV2FPT0WU
CaR-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnT5TWM2OD1|Mz65PFIzKM7:TR?= NXXRUY1lW0GQR1XS
OE33 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml70TWM2OD1|ND6yPFU2KM7:TR?= MUfTRW5ITVJ?
COLO-800 MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkP3TWM2OD1|ND6zOlQ4KM7:TR?= NFy4dYtUSU6JRWK=
NB14 M2PzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XwNWlEPTB;M{SuOFY5PCEQvF2= MormV2FPT0WU
KURAMOCHI NEHITXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPPTWM2OD1|Nj6xNVk5KM7:TR?= MW\TRW5ITVJ?
SW48 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr0[4RkUUN3ME2zOk4zPDd2IN88US=> Ml7lV2FPT0WU
Daoy NHjVV2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HrN2lEPTB;M{[uOlU{QCEQvF2= MW\TRW5ITVJ?
TGBC24TKB NFixNmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHpNodKSzVyPUO2MlY4KM7:TR?= M4LqTHNCVkeHUh?=
DU-4475 NF7mZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrvcIpEUUN3ME2zOk46ODN|IN88US=> NED5Vo9USU6JRWK=
SW1417 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTN6LkC1OVIh|ryP NYjSS3M4W0GQR1XS
EFO-21 NFvUW4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTreFdKSzVyPUO4Mlk{PDlizszN Ml:zV2FPT0WU
MG-63 MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHlSHRRUUN3ME2zPU4{PDJ2IN88US=> NWTVN|N1W0GQR1XS
LC-2-ad NH74NnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzYOlRZUUN3ME2zPU42PTF{IN88US=> MULTRW5ITVJ?
NOMO-1 M1n5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTN7LkiyO|Qh|ryP NFfxc|dUSU6JRWK=
COLO-741 NVX6TWoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDRXmVKSzVyPUSwMlE{ODRizszN NHXLZm1USU6JRWK=
BxPC-3 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;pUZFKSzVyPUSwMlU3QDZizszN MWrTRW5ITVJ?
HSC-2 M1KzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTRyLkmxNVMh|ryP MYjTRW5ITVJ?
UMC-11 M2Had2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jUUmlEPTB;NEGuNlY{KM7:TR?= MmXYV2FPT0WU
HCC1937 NHjz[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfSZVZ6UUN3ME20Nk44QDR|IN88US=> NGDzdoZUSU6JRWK=
Calu-6 Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTR|LkKzPFIh|ryP M1LUfHNCVkeHUh?=
NCI-H1573 NXrMVHl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrHUWxEUUN3ME20N{4{PDd5IN88US=> MkL2V2FPT0WU
SK-N-AS MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEixe|hKSzVyPUSzMlYxOTlizszN Mn;qV2FPT0WU
PSN1 MmLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkOyTWM2OD12NT6yOVQ5KM7:TR?= MVXTRW5ITVJ?
TE-11 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLRcos3UUN3ME20OU41QDR{IN88US=> Mn;JV2FPT0WU
NCI-H1155 NXTPWJhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTR3Lki5Olch|ryP NHvte|BUSU6JRWK=
KM12 M4rnOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1T5fWlEPTB;NEWuPVA4PiEQvF2= MVfTRW5ITVJ?
RO82-W-1 M1H0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DzdGlEPTB;NE[uPVgzOiEQvF2= MUjTRW5ITVJ?
SW1573 NHjtR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPPcZhKSzVyPUS3MlM4OzZizszN MYPTRW5ITVJ?
CAKI-1 NWPSdolLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTvTWM2OD12OD6yPFQ2KM7:TR?= M2jWUnNCVkeHUh?=
U-118-MG M3q2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\2XmlEPTB;NEiuN|cxOiEQvF2= NX:2[XI4W0GQR1XS
KYSE-520 MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XVe2lEPTB;NEiuOFAyPiEQvF2= MmTvV2FPT0WU
HT55 Mn\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmm2TWM2OD12OT6xOFc1KM7:TR?= MXHTRW5ITVJ?
ChaGo-K-1 NYTRbHhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTR7LkS3PVMh|ryP NG\YO5JUSU6JRWK=
IA-LM MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrBTWM2OD13ND62N|IzKM7:TR?= MX7TRW5ITVJ?
UACC-62 NX;wVmVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTV3LkGwOFYh|ryP MXrTRW5ITVJ?
MKN7 M4DBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nWVmlEPTB;NU[uNFI5PSEQvF2= MoXEV2FPT0WU
HPAF-II NGLGWVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\Bd2lEPTB;NU[uOFA4OyEQvF2= NHHm[lJUSU6JRWK=
NTERA-S-cl-D1 M2\FVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfWSpF4UUN3ME21O{44PzhizszN Mmr3V2FPT0WU
FTC-133 M2XUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;YV2lEPTB;NUiuNFk3QSEQvF2= M{fK[HNCVkeHUh?=
MHH-ES-1 M4rHemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Hkc2lEPTB;NUiuOFgyPCEQvF2= NILHPWdUSU6JRWK=
JVM-2 NHvoTlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXDO3M{UUN3ME21PE46PTB4IN88US=> M3:ybnNCVkeHUh?=
TCCSUP NFnGc5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTV7LkWyO|kh|ryP NHjpeFZUSU6JRWK=
COLO-824 M4Tx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnOwTWM2OD14MD6wO|E6KM7:TR?= NYfDTXczW0GQR1XS
647-V NGTUb3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\HTWM2OD14MD6xN|Q4KM7:TR?= MXrTRW5ITVJ?
HD-MY-Z NWPtR41pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTZyLkWyPVQh|ryP NVLrWmhVW0GQR1XS
LS-411N MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXrUlV3UUN3ME22NU4{QTB|IN88US=> NYrIVWVlW0GQR1XS
NCI-H596 M4Dq[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjJVYJtUUN3ME22Nk44PDl4IN88US=> NYG4SJZTW0GQR1XS
C-33-A NXi3PHRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTZ2LkC5OVch|ryP M4\qWnNCVkeHUh?=
BHY NW[ybXE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHJeJdKSzVyPU[0MlEzPDVizszN NX\CUpRRW0GQR1XS
KGN MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnuTWM2OD14ND61OVE1KM7:TR?= NIG1PYtUSU6JRWK=
NCI-H1092 M4m1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TBRmlEPTB;NkWuNFA6PSEQvF2= NV7tOmpDW0GQR1XS
MZ1-PC M1;lS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTZ3LkW2OFkh|ryP MoT6V2FPT0WU
LB831-BLC M2LxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTZ3Lki0PFEh|ryP NE[4U3ZUSU6JRWK=
SW620 M4m3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTZ4LkKwN|kh|ryP MYrTRW5ITVJ?
HuO-3N1 MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrLVXNKSzVyPU[4MlMzOzhizszN MonLV2FPT0WU
SK-HEP-1 NUfv[ppNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTZ7Lkm0PFYh|ryP NGe1[5dUSU6JRWK=
LCLC-103H MkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjW[phKSzVyPUewMlY4ODVizszN M1;2fHNCVkeHUh?=
KYSE-70 Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVmyOot7UUN3ME23NE44QDN3IN88US=> NU[0[o1rW0GQR1XS
Mewo MnzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTdzLkWwOUDPxE1? MkS3V2FPT0WU
COLO-668 NXu4fZdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XDcGlEPTB;N{GuPFQ2OSEQvF2= MUjTRW5ITVJ?
NCI-H522 NWjHcZlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvMVmdwUUN3ME23Nk4{PDF|IN88US=> MX7TRW5ITVJ?
NCI-H1437 NHvqZWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTd2LkSwOFgh|ryP M33uVHNCVkeHUh?=
U-266 M1K5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHnTWM2OD15NT60OVE3KM7:TR?= M3rGOnNCVkeHUh?=
MC116 M3WzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTd3LkW3NFgh|ryP NH;1RpFUSU6JRWK=
PANC-10-05 NV[2SnZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4P5V2lEPTB;N{euOFI1OyEQvF2= Ml60V2FPT0WU
KYSE-180 NI\DU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\yemlEPTB;N{euOVQ2PCEQvF2= NULDelZwW0GQR1XS
JAR MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzHSoFKSzVyPUe5MlA2PDZizszN NHXhe2dUSU6JRWK=
CAL-62 MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\VZ|V2UUN3ME24NE4xQTVizszN NEjrfWJUSU6JRWK=
A3-KAW NWTJWIdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7zW5ZxUUN3ME24NE4zOTV2IN88US=> MkDDV2FPT0WU
PANC-08-13 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fqdmlEPTB;OEGuNVc3QCEQvF2= NWW2OVVGW0GQR1XS
HSC-3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4L6c2lEPTB;OEOuN|A4OSEQvF2= NYnWUmNZW0GQR1XS
HTC-C3 NInQc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTh|LkS3NFIh|ryP NX3TZlg6W0GQR1XS
KY821 NUOzcII{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfMWZVKSzVyPUi0MlA5QTJizszN MX3TRW5ITVJ?
DoTc2-4510 MkDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M32x[WlEPTB;OESuNlE5PSEQvF2= M3m5[nNCVkeHUh?=
NCI-H1581 NHXFb41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPPeFZJUUN3ME24OU41PjRzIN88US=> M3eydHNCVkeHUh?=
KARPAS-299 MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEO3O4lKSzVyPUi2MlE6PzdizszN MnzjV2FPT0WU
IST-MEL1 NXn6TlV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnsdpVlUUN3ME24Ok45QDd{IN88US=> NEjUTWNUSU6JRWK=
KP-N-YS MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NES0ZZRKSzVyPUi5MlkxOjhizszN NH;TO3BUSU6JRWK=
KYSE-410 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTGbVlKUUN3ME25NU41ODR{IN88US=> NVz4[nQ4W0GQR1XS
TE-10 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnT0TWM2OD17MT61OlEyKM7:TR?= Mm\xV2FPT0WU
SK-MEL-1 NW\o[lk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vER2lEPTB;OUKuPVExPiEQvF2= MUHTRW5ITVJ?
COLO-792 M{OxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnwTWM2OD17NT6yOVY1KM7:TR?= NIr5NItUSU6JRWK=
SCH MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TVVmlEPTB;OU[uN|g4PyEQvF2= M1j3PHNCVkeHUh?=
NCI-H1792 M135O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTKZ5ZKSzVyPUm2Mlg6QTJizszN NUC2NW82W0GQR1XS
NCI-H2029 NYXOSFI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTETWM2OD17Nj65OVY3KM7:TR?= NIP6SIFUSU6JRWK=
SW684 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHVTWM2OD17OD62OlU1KM7:TR?= MnP6V2FPT0WU
NCI-H209 NIPmSVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFKzfYNKSzVyPUGwNE4yOjFizszN MlO5V2FPT0WU
HLE M4LEVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2S5NWlEPTB;MUC1MlI5OiEQvF2= NGXYZY1USU6JRWK=
GOTO NH3FRmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4O1TmlEPTB;MUC3Mlc4PyEQvF2= MWfTRW5ITVJ?
NCI-H1793 NGPOdmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLmNVlKSzVyPUGwPU4zQCEQvF2= M{HINHNCVkeHUh?=
D-392MG NHjyPYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTFzNz6zPVgh|ryP NITIWGZUSU6JRWK=
SW1990 NIKwZ2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rwOWlEPTB;MUKwMlk2OSEQvF2= Mn7KV2FPT0WU
ML-2 NXm5U4hUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2q0UWlEPTB;MUKxMlY4PiEQvF2= NHHhflVUSU6JRWK=
NCI-H2452 MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\zXGlEPTB;MUKyMlIyKM7:TR?= NVzPXYtbW0GQR1XS
SK-MEL-30 NXHQO49UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjPTWM2OD1zMkOuNlQ1KM7:TR?= MY\TRW5ITVJ?
SN12C MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jJOmlEPTB;MUK0MlE4PiEQvF2= NX7KSHJ2W0GQR1XS
NCI-H1770 NXHKXHhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrYTWM2OD1zMkWuOVE1KM7:TR?= MWTTRW5ITVJ?
SF268 NHy1W5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTF{Nj6xOVgh|ryP MV\TRW5ITVJ?
BALL-1 M1WwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTF{Nj6yN{DPxE1? NHnZTpVUSU6JRWK=
COLO-679 M{XkdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljuTWM2OD1zMk[uO|U{KM7:TR?= Mmf6V2FPT0WU
A2780 NFi2NZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXQOFlKSzVyPUGyPE46QDhizszN NVjOZo8xW0GQR1XS
NCI-H1651 NF\1UmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvQV|FTUUN3ME2xN|EvOjR|IN88US=> M3jPN3NCVkeHUh?=
NCI-H2087 NYS1XFBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUewNlQxUUN3ME2xN|EvPDh|IN88US=> M1Gw[3NCVkeHUh?=
U-87-MG M{DFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjCVppKSzVyPUGzN{43ODRizszN M3XKfnNCVkeHUh?=
LB2518-MEL MlPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3QTWM2OD1zM{WuPVk{KM7:TR?= MnPRV2FPT0WU
HCT-116 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPYeIFFUUN3ME2xN|cvOjF5IN88US=> NXfIXo9xW0GQR1XS
Ca9-22 NWLmd4RRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTF|OT64N|Mh|ryP MUjTRW5ITVJ?
COR-L88 NWO0RVN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fNNWlEPTB;MUSyMlE1KM7:TR?= NUnGU3FrW0GQR1XS
CP50-MEL-B NXvp[3B[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPJc4tKSzVyPUG0OE42ODFizszN M17wPXNCVkeHUh?=
OVCAR-8 NWjuUoZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGf4do1KSzVyPUG0OU43OzZizszN MWnTRW5ITVJ?
SK-MEL-3 NF34e|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\TdWlEPTB;MUS3Mlg4QCEQvF2= Ml7BV2FPT0WU
GT3TKB NGrLVlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnGZpI2UUN3ME2xOFkvQTJ6IN88US=> NF3rT3dUSU6JRWK=
KYSE-450 NHiwfZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnTcmdWUUN3ME2xOVEvPTN7IN88US=> MWnTRW5ITVJ?
CAPAN-1 Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLTTWM2OD1zNUOuNFY1KM7:TR?= MUnTRW5ITVJ?
BEN MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfLTJNKSzVyPUG1N{46OjhizszN MlrTV2FPT0WU
NCI-H1304 NEfWXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zyU2lEPTB;MUW0MlY6PCEQvF2= MXXTRW5ITVJ?
KU812 M{jTO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH25UVBKSzVyPUG1PE43PzRizszN NUL2WpU3W0GQR1XS
Capan-2 MnnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnRRZFKSzVyPUG2NE42PTNizszN NHLFWpZUSU6JRWK=
A673 NH;UdZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;6PWpKSzVyPUG2NU44ODVizszN NGnLN5pUSU6JRWK=
SAS MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2W4WWlEPTB;MU[yMlY4QCEQvF2= M121PHNCVkeHUh?=
NY MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvJN21KSzVyPUG2OU4{OTRizszN MWPTRW5ITVJ?
HCE-4 M2fFe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1njNmlEPTB;MU[2Mlg1PSEQvF2= MXfTRW5ITVJ?
MDA-MB-231 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rXR2lEPTB;MUe3MlUxOyEQvF2= MWjTRW5ITVJ?
no-10 M1;2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PZN2lEPTB;MUe4MlE{PCEQvF2= MUHTRW5ITVJ?
MZ7-mel NYraNoFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDaTWM2OD1zN{iuOFY4KM7:TR?= NXX1[m1qW0GQR1XS
NCI-H82 NXn2c4d4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTF6MD6xOlUh|ryP NHPGRo9USU6JRWK=
CAL-72 NEjDWIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXjRZVSUUN3ME2xPFUvODV2IN88US=> M2rsU3NCVkeHUh?=
NCI-SNU-5 NEXwWpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mle5TWM2OD1zOE[uPFQh|ryP NVziNpo2W0GQR1XS
OVCAR-4 NYPXbGJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlL5TWM2OD1zOEiuN|M{KM7:TR?= NVr0SId4W0GQR1XS
SCC-9 NVrEcm52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTEZYZKSzVyPUG5NUDPxE1? MlztV2FPT0WU
KYSE-150 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG5XldKSzVyPUG5NU45QDhizszN NVLOSGdQW0GQR1XS
HT-29 M3nwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHQTWM2OD1{MEGuNlEzKM7:TR?= M4XMWnNCVkeHUh?=
COLO-678 NEX6VlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJyMT60OUDPxE1? M{TU[3NCVkeHUh?=
NCI-H650 M{HmVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPBTWM2OD1{MEKuNVA{KM7:TR?= MWjTRW5ITVJ?
HuCCT1 NX7jfFhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJyND6yNFgh|ryP MlzZV2FPT0WU
SW1116 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrDTWM2OD1{MEeuNFc4KM7:TR?= NGr2ZldUSU6JRWK=
DBTRG-05MG M4nLOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTJyNz65NFkh|ryP MYfTRW5ITVJ?
SW982 MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fpT2lEPTB;MkC3Mlk1QCEQvF2= M4ryUnNCVkeHUh?=
RCM-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;iTWM2OD1{MUSuO|YzKM7:TR?= NG\DWIZUSU6JRWK=
COLO-320-HSR NXv5[4xmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DG[WlEPTB;MkG2MlEzPSEQvF2= MV;TRW5ITVJ?
KNS-42 NXPOV3RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{facmlEPTB;MkG2MlU4PCEQvF2= MV\TRW5ITVJ?
C2BBe1 MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzVbJVKSzVyPUKzNU46ODVizszN MXPTRW5ITVJ?
CCRF-CEM NUToe5JbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWP6cI84UUN3ME2yOFMvPzl3IN88US=> NEWyfG1USU6JRWK=
SH-4 MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rWVGlEPTB;MkS2MlA6KM7:TR?= MV7TRW5ITVJ?
LS-1034 NHS1U|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnG5TWM2OD1{NE[uNlY3KM7:TR?= NVr3RmFrW0GQR1XS
NCI-H2347 MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTBTWM2OD1{NEeuO|E{KM7:TR?= M2nZ[XNCVkeHUh?=
RPMI-8866 M2PzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HaSmlEPTB;MkS5MlI4KM7:TR?= MVjTRW5ITVJ?
GAK MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLy[21KSzVyPUK1N{4xODJizszN MVjTRW5ITVJ?
NB6 NIHTVmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2G4R2lEPTB;MkewMlEh|ryP Moi2V2FPT0WU
COLO-680N MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJ5Mj61Nlch|ryP NFnrTYdUSU6JRWK=
RERF-LC-MS MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTnbHc3UUN3ME2yO|YvODB5IN88US=> MYDTRW5ITVJ?
TGBC11TKB Mln3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrXVmJKSzVyPUK3PE4yPzhizszN NUTlcWJzW0GQR1XS
C8166 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTJ5OD61NFYh|ryP MkD5V2FPT0WU
HDLM-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJ7ND60NFkh|ryP NXLZR4JnW0GQR1XS
IGR-1 NIO3coNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIe4cplKSzVyPUK5OU43PTlizszN NGrUcVlUSU6JRWK=
FADU M1T5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTJ7Nz61NUDPxE1? M335THNCVkeHUh?=
L-428 NVLHOFlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\VUZVKSzVyPUK5O{43OTZizszN M4HteXNCVkeHUh?=
LU-65 MorES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3qTWM2OD1|MESuN|Ih|ryP M4TSd3NCVkeHUh?=
HEL MlXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTNyOT65PFMh|ryP NULzOJdYW0GQR1XS
NCI-H810 M1nMS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUixeGlLUUN3ME2zNVAvPTdizszN MWfTRW5ITVJ?
C3A NIiwPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{i4O2lEPTB;M{GxMlgxOiEQvF2= MV\TRW5ITVJ?
NCI-H630 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnkTWM2OD1|M{KuNlk1KM7:TR?= NUTaeohtW0GQR1XS
KP-N-YN NYHEWHU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTN2MT6xNlMh|ryP NH\EZmhUSU6JRWK=
MOLT-13 Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTN2Mj6zNlYh|ryP MX7TRW5ITVJ?
NCI-H1993 M3n5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTVTGFKSzVyPUO0Nk4{PjVizszN MYTTRW5ITVJ?
BE-13 M1zIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjUbIVKSzVyPUO0OE4yPjdizszN NITlb5pUSU6JRWK=
IST-SL1 NWLlT3RrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnqTWM2OD1|NEeuOFAyKM7:TR?= MoDZV2FPT0WU
TE-9 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\FRWNKSzVyPUO2N{42QDlizszN M1TmenNCVkeHUh?=
LU-135 MkS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;BcZFKSzVyPUO2O{4xOzVizszN MXfTRW5ITVJ?
T84 NYrW[ItVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\jTWM2OD1|N{SuO|EzKM7:TR?= M4i3[nNCVkeHUh?=
K-562 M1PFdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3m5bGlEPTB;M{izMlM3KM7:TR?= Ml\FV2FPT0WU
SBC-5 Mon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vOb2lEPTB;M{i2Mlk5PSEQvF2= NHXaXXNUSU6JRWK=
NB17 Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvMcXg6UUN3ME2zPVIvPTl4IN88US=> MYrTRW5ITVJ?
NCI-H2052 NWrFfXBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTN7OD60O|Ih|ryP Mn23V2FPT0WU
HCC38 MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1m1T2lEPTB;NECxMlU6OyEQvF2= NEXpOlVUSU6JRWK=
NCI-H69 M3;uUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGqwVphKSzVyPUS0NU4xQDNizszN NUDIdY1ZW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]

Protocol

Kinase Assay:[4]
+ Expand

Akt kinases assay:

Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.
Cell Research:[2]
+ Expand
  • Cell lines: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
  • Concentrations: 0, 0.3, 1 and 3 μM
  • Incubation Time: 72 or 96 hours
  • Method: MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
  • Formulation: Formulated in 30% Captisol
  • Dosages: 120 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL (29.14 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 15% Captisol 17 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 480.39
Formula

C25H21N5O.2HCl

CAS No. 1032350-13-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01306045 Recruiting Carcinoma, Non-Small-Cell Lung|Carcinoma, Small Cell Lung|Carcinoma, Thymic National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 21, 2011 Phase 2
NCT01802320 Active, not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01783171 Active, not recruiting Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 2013 Phase 1
NCT01776008 Active, not recruiting Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy MK-2206 2HCl | MK-2206 2HCl supplier | purchase MK-2206 2HCl | MK-2206 2HCl cost | MK-2206 2HCl manufacturer | order MK-2206 2HCl | MK-2206 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID